ABBV vs ABT

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Abbott Laboratories exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt-to-equity ratio of 0.27. However, the stock is currently in a severe technical downtrend (0/100) and trades at a significant premium to its Graham Number ($50.12) and Intrinsic Value ($26.04). While analyst targets suggest significant upside to $131.44, the combination of bearish insider selling and poor short-term price performance offsets the strong balance sheet.